Lyme disease is caused by Borrelia spirochetes of three known taxospecies, Borrelia burgdorferi, Borrelia garinii, and Borrelia afzelii (3, 14) . Lyme disease borreliae demonstrate marked antigenic heterogeneity at both the inter-and intraspecies levels (8, 9, 26, 27, 34, 36) . This property is being investigated in detail for borrelial outer surface proteins (Osps) in the context of vaccine development. Differences in antigen compositions among borrelial species may result in regional variation in the clinical presentation and immune responses in Lyme disease. Thus, B. burgdorferi sensu stricto, the prevailing species in the United States (3, 30) , is commonly associated with rheumatological manifestations of Lyme disease (2) . On the other hand, the most common Euroasian species of Lyme disease borreliae, B. garinii and B. afzelii (3, 14) , are mainly associated with neurological and dermatological complications, respectively (2, 16, 33, 35, 38) . Polymorphism of borrelial antigens may also influence the serodiagnosis of Lyme disease. Previously, a remarkable difference in the seroreactivity patterns of American and European Lyme borreliosis patients was demonstrated by immunoblot analysis with the North American strain B31 of B. burgdorferi sensu stricto (4) . In another study, a tendency towards a stronger immune response to the infecting B. burgdorferi sensu lato isolate was noted in neuroborreliosis patients tested by the enzyme immunoassay (EIA) and immunoblot analysis (21, 22) . In two recent studies, sera from neuroborreliosis patients were found to react preferentially against B. garinii in immunoblot analysis (2, 16) . In addition, sera from all of a group of patients with acrodermatitis chronicum athrophicans exhibited stronger reactivity with the antigens of B. afzelii, while the sera from half of the group of Lyme disease patients with arthritis reacted most strongly with the antigens of B. burgdorferi (2) . Variable seroreactivity against different Lyme disease Borrelia species was also demonstrated in a group of Lyme disease patients tested by the EIA (25) .
Most Lyme disease in Sweden is caused by two species of Borrelia. B. afzelii was originally isolated in southern Sweden (1), which was considered to be the only area of endemicity in the country. Recently, B. garinii was recovered from ticks collected on the island of Norrbyskär in northern Sweden, and a case of endemic Lyme disease was reported (11, 13) . Notably, the serum and the cerebrospinal fluid from a neuroborreliosis patient from Norrbyskär reacted considerably more strongly in immunoblot analysis with a local isolate of B. garinii than with B. afzelii (11) .
In this study, we compared the performances of serological assays based on antigenic preparations from two different Lyme disease Borrelia species. Individuals from epidemiological and clinical settings associated with Lyme disease were tested for the immunoglobulin G (IgG) antibody response against the outer membrane-associated proteins of B. burgdorferi and B. garinii. In addition, the commercially available flagellum EIA, which is used as a routine serodiagnostic test for Lyme disease in Scandinavia, was used to measure the seroprevalence of antiflagellum antibodies in the northern Swedish population.
MATERIALS AND METHODS
Antigens. The low-passage-number isolates of Lyme disease Borrelia spp. used in this study were B. burgdorferi B31 (passage 5), a tick isolate from North America (ATCC 35210), and B. garinii NBS16 (passage 3), a tick isolate from the island of Norrbyskär in northern Sweden (11, 13) . Borreliae were grown in BSKII medium (5) . The fraction of borrelial outer membrane-associated proteins, designated BF, was obtained by n-octyl-␤-D-glucopyranoside (Sigma) extraction by a method described previously (12, 24) . It was shown that BF increases the specificity of the EIA compared with that when borrelial whole-cell proteins are used. The absence of potentially cross-reactive flagellin and other irrelevant proteins in BF was expected to promote the specificity of the test (12, 24) . In the commercially available EIA kit (Dakopatts, Glostrup, Denmark), purified flagellum of B. afzelii ACAI was used as the antigen (19) .
Immunoblot analyses. To characterize the BF preparations for the presence of Osp and flagellin, as well as for the immunoblot analysis of patient sera, borrelial proteins were separated by sodium dodecyl sulfate-12.5% polyacrylamide gel electrophoresis (SDS-12.5% PAGE). Subsequently, the gels were either stained with Coomassie blue R-250 (Sigma) or subjected to immunoblotting onto an Immobilon-P membrane (Millipore). Nonspecific binding was blocked by incubating the filter for 2 h in 5% bovine serum albumin (BSA) (Sigma) in phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBS-T). The primary and secondary antibodies were diluted with 2.5% BSA in PBS-T (the dilution of human sera was 1:400), and both incubations of the filter for 1 h were followed by washing in PBS-T. In the development reaction the substrate for alkaline phosphatase was 5-bromo-4-chloro-3-indolylphosphate (Sigma). Murine monoclonal antibodies H5332 (10), 84C (a kind gift from D. D. Thomas), and H9724 (6), as well as rabbit polyclonal anti-OspC antiserum (kindly provided by A. G. Barbour), were used in immunoblot analysis to assess the protein preparations for the presence of OspA, OspB, flagellin, and OspC, respectively.
Serum samples. Subjects in the seroepidemiological study included summer residents on the island of Norrbyskär, which is located in the northern part of the Gulf of Bothnia. Sera were collected from 148 apparently healthy individuals (age 4 to 80 years), who had spent most of at least two summers on Norrbyskär. Summer residents bitten by ticks outside Norrbyskär were excluded from the study. The control population, consisting of 173 persons age 5 to 65 years, was from the province of Lappland in northern Sweden, an area where Lyme borreliosis is not known to be endemic. Both populations investigated were sampled before the start of the tick season.
The serodiagnostic study was performed with reference sera from 40 Lyme disease patients from the United States. The serum samples and clinical summaries were provided by the Centers for Disease Control and Prevention, Fort Collins, Colo. The Lyme disease cases were clinically classified into the stages of localized, disseminated, or persistent infection according to the guidelines described elsewhere (31) .
EIA. In the BF-EIA each well of the microtiter plate was coated overnight at room temperature with 250 ng of protein preparation in 50 l of PBS. Unbound proteins were removed by washing twice with PBS. The rest of the procedure was performed according to the protocol of the manufacturer (Dakopatts) for both the commercial flagellum EIA and the BF-EIA. Briefly, serum samples were diluted 1:200 in 0.5% BSA in PBS-T, and 100 l of diluted serum was placed in each of the two wells assigned for the individual sample and incubated at room temperature for 2 h. After extensive washing with 0.1 M NaCl containing 0.1% Tween 20, peroxidase-conjugated rabbit anti-human IgG diluted in PBS-T was added and incubated at room temperature for 1 h. After washing, 100 l of citrate buffer (pH 5.0) containing chromogen (o-phenylenediamine dihydrochloride) and H 2 O 2 was placed in the wells. After incubation in the dark for 10 min, the reaction was stopped by adding 100 l of 0.85 M sulfuric acid, and the optical density (OD) was measured at 492 nm. Buffer and positive control sera were included on each plate to standardize the OD values between runs.
Statistical analyses. A 97% specific cutoff level with respect to the control was chosen to estimate the seropositivity rate in the Norrbyskär population. This cutoff excluded an excess of false-positive results but allowed a sufficient interval of OD values to be included in the comparison of seropositivity rates in the two populations. Lyme disease patient sera were considered positive at an OD of Ն0.20 (test specificity Ն95%) for both B. burgdorferi B31 and B. garinii NBS16 BF-EIAs. The chi-square test or Fisher's exact test was used to compare seropositivity rates. The seroreactivities of the patient sera in the two BF-EIAs were compared by the Wilcoxon signed rank test. P Ͻ 0.05 was considered statistically significant.
RESULTS
Antigen preparations. The protein profiles of Coomassie blue-stained whole-cell and BF preparations of both B. burgdorferi B31 and B. garinii NBS16 are compared in Fig. 1 . In the BF preparations OspA, OspB, and OspC were characterized by immunoblot analysis (data not shown) with monoclonal (anti-OspA and anti-OspB) and polyclonal (anti-OspC) antibodies. Preparations from both species contained detectable OspA, OspB, and OspC; however, B. garinii NBS16 did not react with the anti-OspB monoclonal antibody 84C. The Osps reactive with the respective antibody in the immunoblot analysis of the BF are shown in Fig. 1 . The absence of flagellin in BF was also demonstrated by immunoblot analysis (data not shown).
Serological investigation of the population at risk. The frequency distributions of the anti-Borrelia IgG response measured by BF-EIAs and the flagellum EIA, in both the control group and the summer residents of Norrbyskär, are presented in Fig. 2 . In the BF-EIA with either B. burgdorferi B31 or B. garinii NBS16, the OD distribution patterns in the control population were very similar and resulted in identical 97th percentile cutoff values (OD ϭ 0.22). In the EIA with BF of B. garinii NBS16, summer residents from Norrbyskär demonstrated a significantly higher (P ϭ 0.005) seropositivity rate (11.5%) than the control population (2.9%), whereas no significant difference between the two populations was found in the BF-EIA with B. burgdorferi B31 ( Table 1) . Eight of the 17 (47.1%) anti-B. garinii BF-positive specimens from the Norrbyskär population were found within the moderately positive range (OD ϭ 0.23 to 0.25). The OD values of 17 other sera were clustered just below (OD ϭ 0.21) or were identical to (OD ϭ 0.22) the cutoff value. In the Norrbyskär population the BF-EIA with B. garinii NBS16 revealed significantly more seropositive specimens (P ϭ 0.014) than that with B. burgdorferi B31 (Table 1 ).
In the flagellum EIA, both the control and Norrbyskär populations demonstrated low background prevalences of the antiflagellum antibody (Fig. 2) . No difference between the seropositivity rates in the investigated groups was seen (Table 1) . Notably, the 100% specific cutoff in the control population (OD ϭ 0.18), was considerably lower than the cutoff (OD ϭ 0.24) suggested by the manufacturer of the flagellum EIA. Compared with the B. garinii NBS16 BF-EIA, the flagellum EIA identified significantly fewer seropositive specimens (P ϭ 0.022) in the Norrbyskär population. Only two of six (33.3%) antiflagellum-positive sera were also positive in the B. garinii NBS16 BF-EIA.
Serological investigation of Lyme disease patients. The distributions of OD values of sera from Lyme disease patients tested by the two EIAs are presented in Fig. 3 . The sera were significantly more reactive (P Ͻ 0.0001, Wilcoxon signed rank test) in the B. burgdorferi B31 BF-EIA than in the B. garinii NBS16 BF-EIA. In the group of Lyme disease patients, a total of 57.5% seropositive specimens were found with the B. burgdorferi B31 BF-EIA versus 15.0% (P ϭ 0.0001) seropositive specimens with the B. garinii NBS16 BF-EIA (Table 2 ). All six sera that were positive in the B. garinii NBS16 BF-EIA were also positive in the B. burgdorferi B31 BF-EIA. However, the median OD obtained for these sera in the B. garinii NBS16 BF-EIA (0.41) was significantly lower (P ϭ 0.03) than that in the B. burgdorferi B31 BF-EIA (1.83). All of the sera that were positive in both EIAs were obtained from patients suffering from a disseminated or persistent infection. However, the B. burgdorferi B31 BF-EIA was positive for 94.1% of these patients, whereas significantly fewer (P ϭ 0.013) positive specimens (35.3%) were found in the B. garinii NBS16 BF-EIA. The two assays also differed significantly (P ϭ 0.02) in their ability to detect seropositive patients with localized infection ( Table  2) .
The results of immunoblot analysis of the B. burgdorferi B31 BF-EIA-positive sera from seven patients with localized infection are presented in Fig. 4 . The reactivity of these sera is directed mainly against OspC. Five (71.4%) of the seven sera reacted strongly against the OspC protein of B. burgdorferi B31. None of the sera showed significant reactivity in immunoblot analysis with the BF of B. garinii NBS16. It is interesting that the OD values from the B. burgdorferi B31 BF-EIA and the immunoblot reactivities do not correlate well. The sera from patients 1, 2, and 7 yielded higher OD values than those from patients 3 and 6; however, there was no apparent difference in the reactivities of these sera on the blot. Furthermore, the sera from patients 4 and 5 gave OD values similar to those of the sera from patients 3 and 6 but lacked anti-OspC reactivity.
B. burgdorferi B31 BF-EIA-positive sera from 16 patients with disseminated or persistent infection were also assayed by immunoblot analysis (data not shown). Eighty-one percent (13 patients) of these sera reacted against different antigens of B. burgdorferi B31 but against only a small number of proteins of B. garinii NBS16. In these clinical samples, predominant antiOspC reactivity specific for B. burgdorferi B31 was found to be significantly less frequent than anti-OspC reactivity in the patients with localized Lyme disease. 
DISCUSSION
In this study, a population at risk for and patients with Lyme disease demonstrated different immune responses against two distinct Lyme disease Borrelia species.
The apparently healthy summer residents of the island of Norrbyskär in northern Sweden, where Lyme borreliosis is endemic, have an increased risk of exposure to Borrelia infection. However, the high seroprevalence in this population was revealed only in the EIA based on the outer membrane-associated proteins of the local isolate of B. garinii NBS16. In this EIA, the seroreactivity patterns in the screened populations diverged mainly because of the presence of moderately positive and borderline reactivities in the population at risk. Moderate and marginal seroreactivities are likely to prevail in apparently healthy individuals from an area of endemicity, whose immune response could be triggered during a subclinical course of infection. The B. burgdorferi B31 BF-EIA failed to discriminate between the Norrbyskär and control populations and revealed significantly fewer seropositive individuals among the population at risk than the B. garinii NBS16 BF-EIA. This suggests that the seroreactivity in the Norrbyskär population is directed specifically against the local isolate of B. garinii.
In contrast, the detection of specific antibodies in a group of Lyme disease patients from the United States was much greater with use of the American B. burgdorferi B31 than with B. garinii NBS16. The two EIAs varied markedly in both the seroreactivities of individual sera and the positivity rates. The B. burgdorferi B31 BF-EIA showed a sensitivity ranging from 30.4% for localized infection to 94.1% for the stages of dissemination or persistence. The reactivities of the different patient sera were always lower in the B. garinii NBS16 BF-EIA, and only six (15.0%) sera from patients with clinically advanced Lyme disease were positive in this assay. None of the patients were positive in only the B. garinii NBS16 BF-EIA, indicating that B. garinii was not the causative agent in any of the American patients. This finding agrees with the commonly held view that Borrelia strains associated with Lyme disease in North America belong to B. burgdorferi sensu stricto and thus show less intraspecies heterogeneity than other Lyme disease borreliae (7, 13, 28, 30, 35, 39) .
The EIA-positive sera from Lyme disease patients were analyzed by immunoblot with the aim of determining the borrelial antigens responsible for triggering the species-specific immune responses. Patients with localized infection developed antibodies against a limited number of spirochetal antigens, reacting most strongly against OspC of B. burgdorferi B31. The reactivity of the patient sera against antigens of B. garinii NBS16, including OspC, was very weak or undetectable. It has been previously shown that patients from Europe and the United States with early Lyme disease frequently develop antibodies against OspC (29, 32, 37) . On the other hand, OspC is antigenically polymorphic, since polyclonal antiserum raised against OspC has serotype-restricted specificity (32, 36) . It is therefore very likely that in early Lyme disease, OspC of a particular Borrelia species defines most of the species specificity of the immune response.
In immunoblot analysis all sera from patients with disseminated or persistent infection were nonreactive or only weakly reactive against BF or B. garinii NBS16. When tested against B. burgdorferi B31 antigens, the majority of these sera recognized many different borrelial proteins. In contrast to the group of patients with localized infection, the dominant anti-OspC reactivity was documented in only a small number of patients with late Lyme disease. Thus, it is likely that, unlike in the localized infection, borrelial outer membrane-associated proteins other than OspC evoke species-specific seroreactivity during the later stages of Lyme disease. OspA and OspB reactivities were shown to participate in the late immune response during Lyme disease, although only in a minority of patients (15, 17, 23, 40) . The genetic and antigenic heterogeneity of these proteins is well established (20, 34, 35) . This may contribute to the diverse seroreactivity of a certain fraction of Lyme disease patient sera in the assays based on different Borrelia species.
Although sera with high titers in EIA tended to correlate with a more-abundant banding pattern in immunoblot analysis, approximately 20% of the B. burgdorferi B31 BF-EIA-positive sera displayed no bands on the blots. A similar discrepancy has been previously observed by other investigators (23, 32) . It was suggested that the denaturing conditions of the immunoblot procedure may cause conformational changes of the epitopes and thus prevent them from interacting with the specific antibody (32) . Conversely, in the EIA the structure of the antigenic determinants remains intact because of the covalent interaction between the solid phase and the coated proteins. Therefore, the EIA is likely to be more suitable for the quantitative evaluation of the immune response.
The occurrence of anti-Borrelia species-specific seroreactivity has several practical implications. Serological screening for Lyme borreliosis in epidemiological or clinical settings would benefit from tests with antigens derived from the Lyme disease Borrelia species from a particular geographical region. On the other hand, species-wide sensitivity of a serodiagnostic assay could possibly be achieved by including potent immunogens derived from different Lyme disease Borrelia species (12, 32) . Finally, the measurement of antibodies against a panel of Lyme disease Borrelia spp. may provide epidemiological data on which borrelial species a particular population has been exposed to.
The Norrbyskär and control populations, both sampled before the start of tick activity, did not show any difference in seroreactivity when the commercially available flagellum EIA was used. In a similar study with individuals from the south- eastern part of Sweden, the antiflagellum seroprevalence during the late summer peak of tick activity in a presumed at-risk population was 28%, compared with 2% in the control population (18) . It is possible that in a healthy population from an area of endemicity, the level of antiflagellum antibody decreases to diagnostically insignificant levels by the start of the annual epidemiological cycle. In the present study, only onethird of B. garinii BF-EIA-positive sera contained increased levels of antiflagellum antibody. This suggests that the antiflagellum and anti-BF immune responses are not synchronized in the population in the area of endemicity. Thus, the measurement of antibodies against the outer membrane proteins of Lyme disease Borrelia spp. better reflects the immune events occurring in the population. Furthermore, in the flagellum EIA, the control population from the province of Lappland demonstrated low background antiflagellum seroprevalence, which is probably typical for northern Sweden. It is important to note that the 100% specific cutoff level of the antiflagellum seroreactivity in this population was considerably lower than the cutoff established by the manufacturer of the assay. The latter cutoff is usually referred to in routine serodiagnostic work in Scandinavia, irrespective of geographical differences in antiborrelial seroprevalence. Thus, the interpretation guidelines supplied with commercially available diagnostic kits should be critically evaluated by the users in individual laboratories. Instead, serodiagnostic criteria should be developed on the basis of seroepidemiological screening of geographically relevant populations.
The present study shows that antigenic heterogeneity of Lyme disease Borrelia spp. may influence the performance of serological tests. We believe that the reliability of serological investigations increases when the immunological response to a specific Lyme disease Borrelia species in a particular region is measured.
